Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Maintenance regorafenib versus placebo after first-line chemotherapy in HER2-negative advanced gastric or gastroesophageal junction cancer
2014-004395-28Phase 2Terminated
- Sponsor
- Azienda Ospedaliero-Universitaria di Parma
- Start
- Oct 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in gastric cancer (GC) and esophagogastric junction cancer comparing Maintenance regorafenib with Maintenance placebo (2 arms). Primary endpoint: Progression-free survival. Started Oct 2014; status: terminated.
02
Drugs
regorafenib
03
Conditions
gastric cancer (GC)esophagogastric junction cancer
Beyond the preview
Go deeper on 2014-004395-28.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-004395-28.